COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,696 Articles (22,913 medRxiv, 8,783 bioRxiv)

Most recent first Previous |  Page 513: Articles 5121-5130  | Next

An Explainable Host Genetic Severity Predictor Model for COVID-19 Patients
Onoja, A., Raimondi, F., Nanni, M.
10.1101/2023.03.06.23286869 — Posted: 2023-03-08
Comparative Effectiveness of Alternative Intervals between First and Second Doses of the mRNA COVID-19 Vaccines: a Trial Emulation Approach
Shioda, K., Breskin, A., Harati, P., Chamberlain, A., Lopman, B., Rogawski McQuade, E. T.
10.1101/2023.03.06.23286848 — Posted: 2023-03-08
Giving a voice to adults with COVID-19: An analysis of open-ended comments from smell longhaulers and non-longhaulers
Menger, N. S., Tognetti, A., Farruggia, M. C., Mucignat, C., Bhutani, S., Cooper, K. W., Rohlfs Dominguez, P., Heinbockel, T., Shields, V., D'Errico, A., Pereda-Loth, V., Pierron, D., Koyama, S., Croijmans, I.
10.1101/2023.03.07.23286910 — Posted: 2023-03-07
Evaluating the theoretical performance of aircraft wastewater monitoring as a tool for SARS-CoV-2 surveillance
Shingleton, J. W., Lilley, C., Wade, M. J.
10.1101/2023.03.07.23286894 — Posted: 2023-03-07
The impact of COVID-19-related disruptions to HPV vaccination - a modelled analysis
Velentzis, L. S., Smith, M. A., Killen, J., Brotherton, J. M., Guy, R., Canfell, K.
10.1101/2023.03.07.23286911 — Posted: 2023-03-07
Development of Fully Human, Bispecific Antibodies that Effectively Block Omicron Variant Pseudovirus Infections
Allen, J. K., Gonzalez, M. A., Kaur, J., Smith, M., You, J., Yang, G., Zha, D., Tian, Z., Al-Shami, A., Shi, C., Molldrem, J. J., Heffernan, T.
10.1101/2023.03.07.531527 — Posted: 2023-03-07
Genome-scale CRISPR-Cas9 screen identifies novel host factors as potential therapeutic targets for SARS-CoV-2 infection.
Sakai, M., Masuda, Y., Tarumoto, Y., Aihara, N., Tsunoda, Y., Iwata, M., Kamiya, Y., Komorizono, R., Noda, T., Yusa, K., Tomonaga, K., Makino, A.
10.1101/2023.03.06.531431 — Posted: 2023-03-07
Unraveling the Interactions between Human DPP4 Receptor, SARS-CoV-2 Variants, and MERS-CoV, converged for Pulmonary Disorders Integrating through Immunoinformatics and Molecular Dynamics
Mallick Gupta, A., Raghavendra, P. B., Roy, A. N., Banerjee, D., Chakrabarti, J.
10.1101/2023.03.06.531252 — Posted: 2023-03-07
SARS-CoV-2 viral replication persists in the human lung for several weeks after onset of symptomatic severe COVID-19 and is associated with attenuated pulmonary immunity and variant-specific clinical sequalae
Tomasicchio, M., Jaumdally, S., Pooran, A., Esmail, A., Wilson, L., Kotze, A., Semple, L., Meier, S., Pillay, K., Roberts, R., Kriel, R., Meldau, R., Oelofse, S., Mandviwala, C., Burns, J., Londt, R., Davids, M., van der Merwe, C., Roomaney, A., Kuhn, L., Perumal, T., Scott, A., Hale, M., Baillie, V., Mahtab, S., Williamson, C., Joseph, R., Sigal, A., Joubert, I., Piercy, J., Thomson, D., Fredericks, D., Miller, M., Nunes, M., Madhi, S., Dheda, K.
10.1101/2023.03.06.23286834 — Posted: 2023-03-07
The significant yet short-term influence of research covidization on journal citation metrics
Zheng, X., Ni, C.
10.1101/2023.03.05.531213 — Posted: 2023-03-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).